AR060120A1 - Medio y metodo para diagnosticar la diabetes - Google Patents

Medio y metodo para diagnosticar la diabetes

Info

Publication number
AR060120A1
AR060120A1 ARP070101229A ARP070101229A AR060120A1 AR 060120 A1 AR060120 A1 AR 060120A1 AR P070101229 A ARP070101229 A AR P070101229A AR P070101229 A ARP070101229 A AR P070101229A AR 060120 A1 AR060120 A1 AR 060120A1
Authority
AR
Argentina
Prior art keywords
diabetes
predisposition
metabolite
acid
metabolites
Prior art date
Application number
ARP070101229A
Other languages
English (en)
Original Assignee
Metanomics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06111705A external-priority patent/EP1837657A1/en
Application filed by Metanomics Gmbh filed Critical Metanomics Gmbh
Publication of AR060120A1 publication Critical patent/AR060120A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para diagnosticar la diabetes o una predisposicion a ésta que comprende determinar por lo menos un metabolito en una muestra de ensayo de un sujeto sospechado de sufrir diabetes o de tener una predisposicion a ésta y comparar dicho por lo menos un metabolito con una referencia, por la cual la diabetes o una predisposicion a ésta debe diagnosticarse. Un conjunto de metabolitos, un conjunto de datos que comprenden valores característicos de los metabolitos y un medio de almacenamiento que comprende dicho conjunto de datos. Además, un sistema que comprende medios para comparar valores característicos de los metabolitos de una muestra ligada en forma funcional a un medio de almacenamiento de datos. Adicionalmente, medios de diagnostico que comprenden por lo menos un metabolito y el uso de dicho por lo menos un metabolito para la fabricacion de medios de diagnostico para diagnosticar la diabetes. Finalmente, un método para identificar metabolitos relacionados con la diabetes. Reivindicacion 1: Un método para diagnosticar la diabetes o una predisposicion a ésta caracterizado porque comprende: (a) determinar por lo menos un metabolito en una muestra de ensayo de un sujeto sospechado de sufrir diabetes o de tener una predisposicion a ésta, dicho por lo menos un metabolito se selecciona del grupo formado por: 1,5-anhidrosorbitol, ácido eicosenoico (C20:1), eritrol, ácido ribonico, ácido tricosanoico (C23:0), pentadecanol, campesterol, ácido maleico y ácido melísico (C30:0); y (b) comparar los resultados de las pruebas de la determinacion del paso (a) con una referencia, por la cual la diabetes o una predisposicion a ésta debe diagnosticarse.
ARP070101229A 2006-03-24 2007-03-23 Medio y metodo para diagnosticar la diabetes AR060120A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111705A EP1837657A1 (en) 2006-03-24 2006-03-24 Means and method for predicting or diagnosing diabetes
EP06120273 2006-09-07

Publications (1)

Publication Number Publication Date
AR060120A1 true AR060120A1 (es) 2008-05-28

Family

ID=38016918

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070101230A AR060121A1 (es) 2006-03-24 2007-03-23 Medio y metodo para predecir la diabetes
ARP070101229A AR060120A1 (es) 2006-03-24 2007-03-23 Medio y metodo para diagnosticar la diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070101230A AR060121A1 (es) 2006-03-24 2007-03-23 Medio y metodo para predecir la diabetes

Country Status (10)

Country Link
US (2) US8216847B2 (es)
EP (6) EP2330423B1 (es)
JP (4) JP5167239B2 (es)
CN (1) CN101438168B (es)
AR (2) AR060121A1 (es)
AT (2) ATE493661T1 (es)
CA (2) CA2647122A1 (es)
DE (2) DE602007011592D1 (es)
ES (4) ES2522818T3 (es)
WO (2) WO2007110358A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5167239B2 (ja) * 2006-03-24 2013-03-21 メタノミクス ゲーエムベーハー 糖尿病の検出手段および検出方法
ES2443540T3 (es) 2007-07-17 2014-02-19 Metabolon, Inc. Biomarcadores para pre-diabetes y métodos que usan los mismos
JPWO2009054350A1 (ja) * 2007-10-25 2011-03-03 味の素株式会社 耐糖能異常の評価方法、耐糖能異常評価装置、耐糖能異常評価方法、耐糖能異常評価システム、耐糖能異常評価プログラムおよび記録媒体、ならびに耐糖能異常の予防・改善物質の探索方法
WO2009153131A1 (en) * 2008-05-28 2009-12-23 Basf Se Means and methods for assessing liver enzyme induction
US8597875B2 (en) 2008-05-28 2013-12-03 Basf Se Method for diagnosing liver toxicity with sex specific biomarkers
US8658427B2 (en) 2008-05-28 2014-02-25 Basf Se Means and methods for assessing increased peroxisomal proliferation
CA2727855A1 (en) * 2008-07-15 2010-01-21 Metanomics Health Gmbh Means and methods diagnosing gastric bypass and conditions related thereto
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
WO2010109192A1 (en) 2009-03-24 2010-09-30 Anamar Ab Metabolic profiles
EP2438445B1 (en) * 2009-06-04 2014-07-16 Metanomics Health GmbH Methods for diagnosing prostate carcinomas
EP2464966A1 (en) * 2009-08-13 2012-06-20 Basf Se Means and methods for diagnosingthyroid disorders
US8367359B1 (en) * 2009-10-23 2013-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Metabolic biomarkers for diabetes and insulin resistance
ES2728120T3 (es) * 2010-01-29 2019-10-22 Metanomics Gmbh Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto
WO2012013667A1 (en) * 2010-07-30 2012-02-02 Technische Universität Graz Analyses of analytes by mass spectrometry with values in at least 3 dimensions
WO2012051463A2 (en) * 2010-10-14 2012-04-19 The Regents Of The University Of California Urine metabolomic profile of diabetic kidney disease
AU2011346553A1 (en) * 2010-12-23 2013-07-11 Metanomics Health Gmbh Means and method for predicting diabetes
US20130101984A1 (en) * 2011-10-20 2013-04-25 The Washington University Methods of detecting sleepiness
WO2013132460A2 (en) * 2012-03-09 2013-09-12 Basf Se Means and methods for assessing disorders related to impaired iron adsorption or energy metabolism
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
EP2867669B1 (en) 2012-06-27 2016-12-21 Metanomics Health GmbH Methods for identifying diabetes drugs
WO2014060486A1 (en) 2012-10-18 2014-04-24 Metanomics Gmbh Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample
EP3321686B1 (en) * 2013-01-31 2024-03-13 Metabolon, Inc. Biomarkers related to insulin resistance progression and methods using the same
KR102204498B1 (ko) * 2013-04-09 2021-01-19 아지노모토 가부시키가이샤 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램 제품, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치
CN103616465A (zh) * 2013-10-28 2014-03-05 浙江大学 血液相关脂肪酸谱的建立方法
US20150323520A1 (en) * 2014-05-07 2015-11-12 The Trustees Of The Stevens Institute Of Technology Diagnosis of kidney transplant acute rejection
JP6773951B2 (ja) * 2014-05-30 2020-10-21 学校法人東京医科大学 唾液試料の調製方法
WO2016138232A1 (en) * 2015-02-26 2016-09-01 Wisconsin Alumni Research Foundation Methods for predicting glucoregulatory dysfunction
WO2017003166A1 (ko) * 2015-06-29 2017-01-05 고려대학교 산학협력단 대사체 분석을 이용한 당뇨병 조기 진단용 조성물
CN106979982B (zh) * 2016-01-19 2021-01-05 上海市第六人民医院 一种用于糖尿病风险预测、治疗评价的方法及试剂盒
CN105784829A (zh) * 2016-04-06 2016-07-20 深圳市老年医学研究所 2型糖尿病肾虚证唾液蛋白指纹图谱分子诊断模型建立方法
CN105699663A (zh) * 2016-04-06 2016-06-22 深圳市老年医学研究所 2型糖尿病唾液蛋白指纹图谱分子诊断模型建立方法
SG11201810254UA (en) * 2016-05-17 2018-12-28 Univ Osaka Blood sample analysis method and system, for determining diabetes
US20200033360A1 (en) * 2017-03-31 2020-01-30 Metabolon, Inc. Comprehensive and quantitative lipid and tocopherol analysis
JP7197555B2 (ja) * 2017-08-17 2022-12-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 思春期前の小児期前糖尿病のマーカー
CN108362804B (zh) * 2018-02-27 2019-01-29 山东英盛生物技术有限公司 一种检测血液样品中dha含量的方法及试剂盒
CN109507337B (zh) * 2018-12-29 2022-02-22 上海交通大学医学院附属新华医院 一种基于血尿中代谢产物预测甘地胶囊治疗糖尿病肾病机制的新方法
CN111443143B (zh) * 2020-04-30 2022-04-29 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种快速测定乳粉中胆固醇含量的方法
CN114216851A (zh) * 2020-11-27 2022-03-22 四川大学华西医院 一种基于表面增强拉曼光谱技术的急性胰腺炎评估装置
KR102583808B1 (ko) * 2021-03-05 2023-09-26 경희대학교 산학협력단 눈물을 이용한 당뇨병의 진단 방법 및 키트
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
CN114965753A (zh) * 2022-05-13 2022-08-30 重庆医科大学附属第一医院 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
AU590883B2 (en) * 1985-05-28 1989-11-23 Nippon Kayaku Kabushiki Kaisha Method of quantitative assay for 1,5-anhydroglucitol
JP2540349B2 (ja) * 1988-01-18 1996-10-02 日本化薬株式会社 腎性糖尿検査方法
ES2087165T3 (es) * 1989-11-30 1996-07-16 Croda Int Plc Uso de acido nervonico y de acidos grasos de cadenas largas en el tratamiento de las alteraciones provocadas por la desmielinizacion.
DE4242794A1 (en) 1991-12-18 1993-06-24 Nitto Boseki Co Ltd Quantitative automated determn. of 1,5-anhydro:glucitol - using pyranose oxidase from Basidiomycetes fungi no.52
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
JPH0870893A (ja) * 1994-09-02 1996-03-19 Nippon Kayaku Co Ltd 犬の糖尿病診断法、１，５−アンヒドログルシトールの定量法及びキット
JP3579549B2 (ja) * 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
NZ328976A (en) 1996-02-20 1999-06-29 Kyowa Hakko Kogyo Kk Quantitative determination of 1,5-anhydroglucitol using an enzyme (typically trehalase)
US5965449A (en) 1996-07-03 1999-10-12 Forbes Medi-Tech, Inc. Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders
US5871949A (en) 1996-12-04 1999-02-16 Daiichi Pure Chemicals Co., Ltd. Method of quantitative assay for 1,5-anhydroglucitol and reagent for quantitative assay
JP3129250B2 (ja) * 1997-09-10 2001-01-29 株式会社ミルス生命科学研究所 尿の化学分析方法
CA2291912A1 (en) 1998-12-11 2000-06-11 Kyowa Medex Co., Ltd. Method and reagent for quantitative determination of 1,5-anhydroglucitol
US6518069B1 (en) * 1999-04-22 2003-02-11 Liposcience, Inc. Methods and computer program products for determining risk of developing type 2 diabetes and other insulin resistance related disorders
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
JP2001330599A (ja) * 2000-05-24 2001-11-30 Shimazu S D Kk Ｇｃ／ｍｓによる代謝異常スクリーニング診断装置
US20020068310A1 (en) 2000-10-11 2002-06-06 Mihoko Sasaki Method and reagant for quantitative determination of 1,5-anhydroglucitol
ES2173049B1 (es) * 2001-03-28 2004-01-16 Oleoyl Estrone Developments S Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
EP1417629B1 (en) * 2001-07-06 2008-02-20 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
WO2003027296A1 (fr) * 2001-09-20 2003-04-03 Plantech Research Institute Genes intervenant dans la synthese d'acide gras presentant une liaison double conjuguee trans-11-, cis-13-, et utilisation desdits genes
DK1438420T3 (da) * 2001-09-24 2010-01-18 Lipomics Technologies Inc Fremgangsmåder til anvendelse af kvantitative lipid-metablom-data
AU2003218649B2 (en) 2002-02-28 2007-09-06 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
WO2003078574A2 (en) * 2002-03-11 2003-09-25 Lipomics Technologies, Inc. Novel metabolic targets and markers
US20040132819A1 (en) * 2002-08-06 2004-07-08 Nancy Auestad Appetite control method
JP2004097134A (ja) * 2002-09-11 2004-04-02 Univ Hiroshima 鎖長延長酵素による長鎖脂肪酸の合成法
EP1644007B1 (en) * 2003-05-31 2012-10-10 Pharmachem Laboratories, Inc. Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes
JP4717810B2 (ja) * 2003-06-20 2011-07-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド １型糖尿病と２型糖尿病を識別するためのバイオマーカー
JP4066259B2 (ja) * 2003-09-11 2008-03-26 財団法人大阪産業振興機構 軟体動物由来廃棄物の処理方法
EP1733345A4 (en) * 2004-02-17 2010-11-24 Bodybio Inc NETWORK AND METHODS FOR INTEGRATING RESULTS OF INDIVIDUALIZED CLINICAL TESTS AND NUTRITIONAL TREATMENT
US20050202521A1 (en) 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
EP1754059B1 (en) * 2004-06-09 2010-08-04 Becton, Dickinson and Company Multianalyte sensor
BRPI0514244A (pt) * 2004-08-09 2008-06-03 Enzymotec Ltd produtos alimentìcios para diabéticos
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
JP5167239B2 (ja) 2006-03-24 2013-03-21 メタノミクス ゲーエムベーハー 糖尿病の検出手段および検出方法
ES2443540T3 (es) * 2007-07-17 2014-02-19 Metabolon, Inc. Biomarcadores para pre-diabetes y métodos que usan los mismos

Also Published As

Publication number Publication date
WO2007110358A2 (en) 2007-10-04
ES2522815T3 (es) 2014-11-18
JP5579819B2 (ja) 2014-08-27
EP2339346A2 (en) 2011-06-29
JP2013057672A (ja) 2013-03-28
EP2005189B1 (en) 2010-12-29
CA2647197A1 (en) 2007-10-04
JP2013076703A (ja) 2013-04-25
JP5199994B2 (ja) 2013-05-15
ATE493661T1 (de) 2011-01-15
CA2647122A1 (en) 2007-10-04
JP2009530626A (ja) 2009-08-27
DE602007011592D1 (de) 2011-02-10
US8216847B2 (en) 2012-07-10
JP5167239B2 (ja) 2013-03-21
EP2008108B1 (en) 2010-12-29
EP2339346B1 (en) 2014-09-03
ATE493660T1 (de) 2011-01-15
EP2330423B1 (en) 2014-10-01
CN101438168B (zh) 2013-10-16
ES2522818T3 (es) 2014-11-18
EP2369346B1 (en) 2014-08-27
US20100163720A1 (en) 2010-07-01
DE602007011588D1 (de) 2011-02-10
EP2005189A2 (en) 2008-12-24
WO2007110357A3 (en) 2007-11-15
JP2009530627A (ja) 2009-08-27
WO2007110358A3 (en) 2007-11-15
EP2008108A2 (en) 2008-12-31
EP2369346A3 (en) 2011-11-02
AR060121A1 (es) 2008-05-28
EP2336782A1 (en) 2011-06-22
EP2336782B1 (en) 2014-08-27
EP2369346A2 (en) 2011-09-28
EP2339346A3 (en) 2011-10-19
CN101438168A (zh) 2009-05-20
EP2330423A1 (en) 2011-06-08
ES2522816T3 (es) 2014-11-18
ES2525345T3 (es) 2014-12-22
US8216848B2 (en) 2012-07-10
WO2007110357A2 (en) 2007-10-04
US20100236321A1 (en) 2010-09-23

Similar Documents

Publication Publication Date Title
AR060120A1 (es) Medio y metodo para diagnosticar la diabetes
EP2804001A3 (en) Methods for diagnosing prostate carcinomas
Wu et al. Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease
MX2009000697A (es) Sistema y metodo para medir un analito en una muestra.
WO2007059065A3 (en) Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
NZ701807A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Ayers et al. Procoagulant and platelet-derived microvesicle absolute counts determined by flow cytometry correlates with a measurement of their functional capacity
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008135862A3 (en) Devices and methods for detecting analytes
NZ592365A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009088816A3 (en) Systems and methods for well data analysis
WO2007106224A3 (en) Method of detecting or diagnosing of a neurodegenerative disease or condition
WO2005085292A3 (fr) Procede de detection de la forme libre activable du psa et son utilisation pour le diagnostic des pathologies benignes de la prostate et de l'adenocarcinome de la prostate
WO2004089187A3 (en) Caries risk test for predicting and assessing the risk of disease
WO2008109075A3 (en) Biomarkers and methods for determining sensitivity to ctla-4 antagonists
Anglicheau et al. Discovery and validation of a molecular signature for the noninvasive diagnosis of human renal allograft fibrosis
Javanmardi et al. Diagnostic value of cystatin C for diagnosis of early renal damages in type 2 diabetic mellitus patients: The first experience in Iran
Salgado et al. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension
WO2010051544A3 (en) Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer
BRPI0812875B8 (pt) " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste
EP3185013A3 (en) Biomarkers for determining an allograft tolerant phenotype
WO2007061940A3 (en) Method for detecting an inflammatory disease or cancer
JP2018536170A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure